Posts tagged Psychedelics.
Blogs
9 minute read
It was an invigorating conference at Horizons: Perspectives on Psychedelics, October 15–17, 2026, in New York, which featured important views on the health care industry, federal agency preparation for psychedelic drug regulation, reimbursement, and incorporating psychedelics into patient care protocols.
This post shares insights that the Epstein Becker Green team took away from sitting in on these discussions.
Blogs
2 minute read
In this episode of the Diagnosing Health Care Podcast: Renewed interest in the potential benefits of psychedelic treatments has led to an upsurge in research. Is the first FDA approval of a psychedelic for therapeutic use on the horizon?
Back to Health Law Advisor Blog
Recent Updates
- Psychedelics Move Toward the Mainstream: Lawyers’ Bird’s-Eye View from the Horizons Conference
- CMS Receives Its Exclusion Authority: What Happens Now?
- GLOBE Model Final Rule Drops — but Will It Work on a Smaller Scale?
- Congressional Action on Health Care Cybersecurity: HISAA Is Re-Introduced and the Health Care Cybersecurity and Resiliency Act Moves Forward
- DOJ Corporate Fraud Enforcement Memo: What Health Care Companies Need to Know Now